Mannkind (MNKD) Share-based Compensation (2010 - 2026)
Mannkind (MNKD) posted quarterly Share-based Compensation of $11.3 million for Q1 2026, up 109.84% year-over-year from $5.4 million in Q1 2025, and up 62.08% quarter-over-quarter from $7.0 million in Q4 2025.
Mannkind (MNKD) Share-based Compensation (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has reported Share-based Compensation for 17 consecutive years, with $11.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 109.84% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $11.3 million (down 33.69% YoY), while the FY2025 annual figure was $24.2 million, up 140.58% from the prior year.
- Share-based Compensation grew to $11.3 million in Q1 2026 per MNKD's latest filing, from $7.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $11.3 million in Q1 2026 and bottomed at $2.6 million in Q4 2022.
- Historically, Share-based Compensation has averaged $5.1 million across 5 years, with a median of $4.5 million in 2022.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 210.98% — and 2025, when it declined 17.39%.
- Mannkind's Share-based Compensation stood at $2.6 million in 2022, then jumped by 46.82% to $3.8 million in 2023, then surged by 37.08% to $5.2 million in 2024, then soared by 33.38% to $7.0 million in 2025, then surged by 62.08% to $11.3 million in 2026.
- Business Quant data shows MNKD's Share-based Compensation at $11.3 million in Q1 2026, $7.0 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Mannkind | 1.19 Bn | 1.08 Bn | 94.97 Mn | 10.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.23 Mn |
| Jun 30, 2026 | 10.23 Mn |
| Mar 31, 2026 | 11.30 Mn |
| Mar 31, 2026 | 11.30 Mn |
| Dec 31, 2025 | 6.97 Mn |
| Dec 31, 2025 | 6.97 Mn |
| Sep 30, 2025 | 4.32 Mn |
| Sep 30, 2025 | 4.32 Mn |
| Jun 30, 2025 | 7.52 Mn |
| Jun 30, 2025 | 7.52 Mn |
| Mar 31, 2025 | 5.39 Mn |
| Mar 31, 2025 | 5.39 Mn |
| Sep 30, 2024 | 5.23 Mn |
| Sep 30, 2024 | 5.23 Mn |
| Jun 30, 2024 | 6.43 Mn |
| Jun 30, 2024 | 6.43 Mn |
| Mar 31, 2024 | 3.89 Mn |
| Mar 31, 2024 | 3.89 Mn |
| Dec 31, 2023 | 3.81 Mn |
| Dec 31, 2023 | 3.81 Mn |